Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 1/20 | 0.78 |
| ▸ | DYRK1A | Q13627 | 12/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.69 |
| ▸ | NPC1 | O15118 | 3/20 | 0.69 |
| ▸ | RAB9A | P51151 | 3/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.69 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.69 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.64 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.64 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | GFER | P55789 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1653742 | 0.89 | PIK3CG (0.78) | CLK1DYRK1ACYP3A4NPC1RAB9A | |
| SCHEMBL16747427 | 0.85 | RAB9A (0.71) | CLK1DYRK1ACYP3A4NPC1RAB9A | |
| SCHEMBL1622337 | 0.85 | PIK3CG (0.77) | CLK1DYRK1ACYP3A4NPC1RAB9A | |
| SCHEMBL10170616 | 0.83 | DYRK1A (1.00) | DYRK1ACYP3A4NPC1RAB9ACYP1A2 | |
| SCHEMBL2175580 | 0.83 | DYRK1A (1.00) | DYRK1ACYP3A4NPC1RAB9ACYP1A2 | |
| SCHEMBL2193895 | 0.82 | DYRK1A (0.66) | CLK1DYRK1ACYP3A4NPC1RAB9A | |
| SCHEMBL4501407 | 0.82 | DYRK1A (0.71) | CLK1DYRK1ACYP3A4NPC1RAB9A | |
| SCHEMBL6068168 | 0.82 | ABL1 (0.71) | CLK1NPC1RAB9APIK3CASMN1; SMN2 | |
| SCHEMBL19807983 | 0.82 | DYRK1A (0.79) | DYRK1ACYP3A4NPC1RAB9ACYP1A2 | |
| SCHEMBL715950 | 0.82 | DYRK1A (1.00) | DYRK1ACYP3A4NPC1RAB9ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-03-31 | — | — | US | disclosed |
| CN-113727972-B | Novel hydrazone derivatives having terminal amine groups substituted with aryl or heteroaryl groups and use thereof | 韩国科学技术研究院 | 2024-12-27 | — | — | CN | disclosed |
| CN-112812111-B | Benzothiazole compound and medical application thereof | 中国药科大学 | 2023-01-31 | — | — | CN | disclosed |
| US-20220396553-A1 | NOVEL HYDRAZONE DERIVATIVE IN WHICH TERMINAL AMINE GROUP IS SUBSTITUTED WITH ARYL GROUP OR HETEROARYL GROUP, AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2022-12-15 | — | — | US | disclosed |
| CN-113727972-A | Novel hydrazone derivatives in which terminal amino group is substituted with aryl or heteroaryl group, and use thereof | 韩国科学技术研究院 | 2021-11-30 | — | — | CN | disclosed |
| EP-3901139-A1 | NOVEL HYDRAZONE DERIVATIVE WITH ARYL OR HETEROARYL GROUP SUBSTITUTED AT TERMINAL AMINE GROUP THEREOF AND USE THEREOF | Korea Institute of Science and Technology (KR) | 2021-10-27 | — | — | EP | disclosed |
| CN-112812111-A | Benzothiazole compound and medical application thereof | 中国药科大学 | 2021-05-18 | — | — | CN | disclosed |
| US-8710088-B2 | Pharmaceutical and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2014-04-29 | — | — | US | disclosed |
| US-8710088-B2 | Pharmaceutical and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2014-04-29 | — | — | US | disclosed |
| US-8710088-B2 | Pharmaceutical and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2014-04-29 | — | — | US | disclosed |
| EP-0585873-B1 | Method of preparing disazo pigments | CLARIANT GMBH (DE) | 1997-12-29 | — | — | EP | disclosed |
| US-5559216-A | AZO COUPLING | HOECHST AG (DE) | 1996-09-24 | — | — | US | disclosed |
| US-5493011-A | PIGMENTING HIGH MOLECULAR WEIGHT NATURAL OR SYNTHETIC ORGANIC MATERIALS | HOECHST AG (DE) | 1996-02-20 | — | — | US | disclosed |
| EP-0518909-B1 | WATER-INSOLUBLE AZO DYES, THEIR MANUFACTURE AND USE | HOECHST AG (DE) | 1994-05-25 | — | — | EP | disclosed |
| EP-0585873-A1 | Method of preparing disazo pigments | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-03-09 | — | — | EP | disclosed |
| EP-0518909-A1 | WATER-INSOLUBLE AZO DYES, THEIR MANUFACTURE AND USE. | HOECHST AG (DE) | 1992-12-23 | — | — | EP | disclosed |
| EP-0316649-B1 | WATER INSOLUBLE AZO COLOURING AGENTS, THEIR PREPARATION AND USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-07-22 | — | — | EP | disclosed |
| WO-1991013941-A1 | WATER-INSOLUBLE AZO DYES, THEIR MANUFACTURE AND USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-09-19 | — | — | WO | disclosed |
| US-5026831-A | Water-insoluble disazo colorants having hetero-bicyclic methylene-active compounds as coupling component | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-06-25 | — | — | US | disclosed |
| EP-0316649-A2 | Water insoluble azo colouring agents, their preparation and use | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | ABL1, TH, CYP3A43 | CLK1 2694/4885DYRK1A 1279/4885CYP3A4 27/4885 |
| US-20220396553-A1 | NOVEL HYDRAZONE DERIVATIVE IN WHICH TERMINAL AMINE GROUP IS SUBSTITUTED WITH ARYL GROUP OR HETEROARYL GROUP, AND USE THEREOF | AANAT, NAT1, HNMT | CLK1 3775/4885DYRK1A 3095/4885CYP3A4 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.